Omega Labs, Cannabix develop DOT-like breath drug test panel for recent-use detection

  • Cannabix Technologies partnered with Omega Laboratories to develop and validate a breath-based, DOT-like drug testing panel focused on recent-use detection.
  • The lab method expands Omega’s breath testing beyond cannabinoids to multiple drug classes, using breath aerosols collected with Cannabix’s Breath Collection Unit.
  • Testing is positioned for safety-sensitive, forensic, workplace, and criminal justice use cases where minutes-to-hours detection windows matter.
  • Omega plans to run the breath tests as a laboratory service using mass spectrometry, targeting confirmatory quality and chain-of-custody defensibility.
  • Omega is offering the THC breath test and the expanded panel to existing and new clients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cannabix Technologies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CL99927) on July 08, 2026, and is solely responsible for the information contained therein.